ESC 2022 | REVIVED-BCIS2

The REVIVED-BCI2 included 700 patients with ejection fraction 35% with extended coronary artery disease and plausible PCI.

ESC 2022

Patients were randomized to PCI plus optimal and complete medical treatment (OMT) according to the current guidelines.

347 patients received PCI and 353 OMT.

Primary end point was all cause death and hospitalization for cardiac failure. 

There were no differences between the populations.

At 11-month follow-up, there were no differences in primary end point (PCI 37.2% vs OMT 38%). Neither were there differences in primary end point components or the presence of AMI. 

The need for unplanned revascularization and myocardial ischemia were more frequent in patients receiving OMT.

Ejection fraction at 2 years was 27% at 6 and 12 months with no difference between the strategies. 

Read also: ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function.

Quality of life, according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), was superior in patients receiving PCI at 6 months but with no difference at 2 years. 

We can conclude that this study on patients with severe ventricular dysfunction undergoing OMT at maximal tolerable doses, revascularization with PCI did not result in lower incidence of all cause death or hospitalization for cardiac failure. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....